Company: APM
Filing Date: 2025-12-05
Form Type: 424B5
Source: 0001213900-25-118752
Chunk: 447

Company: Aptorum Group Ltd
Filing Date: 2025-12-05
Form: 424B5
Chunk 447
---
 |        — |   |     |          |    — |     |           |
| Expired or forfeited     |     |        |        — |   |     |          |    — |     |           |
| Outstanding May 31, 2025 |     |        |  511,950 |   |     | $        | 4.66 |     | 5.5 years |
| Exercisable May 31, 2025 |     |        |  263,450 |   |     | $        | 4.96 |     | 4.0 years |

The weighted average grant-date fair value of stock options granted during the years ended May 31, 2024 was $7.00, based on the following weighted average assumptions:

|                         |     | 2024 |     |   |
| Expected term in years  |     |      |  10 |   |
| Expected volatility     |     |      |  81 | % |
| Risk-free interest rate |     |      | 4.1 | % |
| Expected dividend yield |     |      |   0 | % |

<div align='center'>F-18

DIAMIR BIOSCIENCES CORP.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</div>

NOTE 11 — STOCKHOLDERS’ EQUITY(cont.)

In the year ended May 31, 2024, the Company modified the terms of certain of its outstanding stock options representing an aggregate of 140,000 shares. These modifications included a reduction in exercise prices from $7.01 per share to $0.01 per share and the addition of performance and vesting conditions, not currently considered probable of achievement, related to corporate transactions.

In the year ended May 31, 2025, stock-based compensation expense amounted to $24,312, which is included in research and development expenses. In the year ended May 31, 2024, stock-based compensation expense amounted to $194,846, of which $182,912 is included in research and development expenses and $11,934 is included in general and administrative expenses. As of May 31, 2025, unrecognized stock-based compensation expense related to options for which vesting is considered probable was $0. As of May 31, 2025, unrecognized stock-based compensation expense related to options for which vesting is not considered probable was $1,093,712.

In the year ended